Catalent Pharma Solutions has completed the second phase of a US$5.5 million expansion programme at its Missouri-based Kansas City facility. The investment aims to increase the controlled-substance and controlled-temperature storage capabilities for its clinical supply business.
The milestone construction marks the conclusion of a two-year project that has also expanded the facility’s highly-potent, cytotoxic and cold storage clinical drug packaging capabilities.
The latest expansion includes a new Drug Enforcement Administration (DEA) Schedule I and II controlled substance vault, providing the site with an additional 3600 sq ft of storage, as well as additional controlled temperature storage capacity with 450 new pallet locations and 500 new high-density storage locations.
A new sampling room has been installed, as well as a new emergency generator to ensure the security and integrity of samples in storage.
“Catalent customers have benefited from our integrated analytical, oral solid manufacturing, and clinical supply services which our Kansas City campus has offered continuously for over 18 years,” said Kevin Economos, general manager of Clinical Supply Services at the site.
Spanning 450,000 sq ft, the Kansas City facility provides a range of fully integrated support services, from development and analytical support through to packaging and distribution.
The expansions at this site follows the recent announcements of new capabilities and capacity at two of Catalent’s clinical supply facilities in Philadelphia and Singapore.
Catalent operates sites in the US, the UK, Germany, Singapore, Japan and China plus an extended network of more than 50 depots globally.
